| Literature DB >> 33833177 |
Brendan J MacKay, Cameron T Cox1, Ian L Valerio2, Jeffrey A Greenberg3, Gregory M Buncke4, Peter J Evans5, Deana M Mercer6, Desirae M McKee, Ivica Ducic7.
Abstract
ABSTRACT: Events causing acute stress to the health care system, such as the COVID-19 pandemic, place clinical decisions under increased scrutiny. The priority and timing of surgical procedures are critically evaluated under these conditions, yet the optimal timing of procedures is a key consideration in any clinical setting. There is currently no single article consolidating a large body of current evidence on timing of nerve surgery. MEDLINE and EMBASE databases were systematically reviewed for clinical data on nerve repair and reconstruction to define the current understanding of timing and other factors affecting outcomes. Special attention was given to sensory, mixed/motor, nerve compression syndromes, and nerve pain. The data presented in this review may assist surgeons in making sound, evidence-based clinical decisions regarding timing of nerve surgery.Entities:
Mesh:
Year: 2021 PMID: 33833177 PMCID: PMC8560160 DOI: 10.1097/SAP.0000000000002767
Source DB: PubMed Journal: Ann Plast Surg ISSN: 0148-7043 Impact factor: 1.539
Orthopedic surgery case triage
| Emergent—within 6 h |
| • Compartment syndrome |
| • Open fracture |
| • Joint dislocations |
| • Fracture-dislocations |
| • Dysvacular limb/ex fix |
| • Traumatic amp/replant |
| • Septic joint |
| • Abscess |
| • Cauda Equina syndrome |
| Urgent—within 24–48 h |
| • Hip and femur fractures |
| • Pelvis and acetabulum fractures |
| • Long bone (femur, tibia, humerus) fractures |
| • Multiple fractures |
| • Unstable spine fractures or progressive neurologic deficits |
| Acute—within 7 d |
| • Factures in general |
| • Hand/UE |
| • Ankle/tibial plateau, etc |
| • Spine fractures without gross |
| • Instability/cord compromise or neurologic symptoms |
| • Mutliligamentous knee dislocation (s/p initial stabilization [ex fix] if necessary) |
| Semielective |
| • Incarcerated meniscus |
| • Biceps tear/tendon repairs |
| • Nerve transection |
| Elective |
| • Total joint replacement (hip/knee/shoulder/ankle) |
| • Degenerative spine without cord/neurologic compromise |
| • Nonunion without hardware compromise/unstable extremity |
| • Degenerative hand/foot/ankle |
| • Isolated knee ligament/meniscus etc |
| • Hardware removal |
Dr Ficke, AAOS Board of Directors, Johns Hopkins Hospital.
ex fix, external fixation; s/p, status post; UE, upper extremity.
Selected Sections From the American College of Surgeons “Guidelines for Triage of Orthopedic Patients”
| Phase II | Phase III | |||
|---|---|---|---|---|
| Schedule | Reschedule | Schedule | Reschedule | |
| Trauma | All new fractures | Fractures >4 wk old | All new fractures | “Soft tissue injury” |
| Acute traumatic injury | Quad tendon rupture | Patients without a diagnosis | ||
| Nonunions, malunions, infections | Patellar tendon rupture | Malunions, nonunions | ||
| Acute change of a chronic injury | Chronic infections | |||
| Orthopedic oncology | Infection including infected joints | Benign soft tissue masses | Infection including infected joints | |
| Sarcoma/other primary malignancy in a “chemo or radiation” window | Benign bone tumors that can wait | Sarcoma/other primary malignancy in a “chemo or radiation” window | ||
| Aggressive benign tumors (GCT) | Elective joint replacement | Aggressive benign tumors (GCT) | ||
| Impending pathologic fracture (including periprosthetic) | Impending pathologic fracture (including periprosthetic) | |||
| Pathologic fracture | Pathologic fracture | |||
| Shoulder and elbow | Acute severe pain | Shoulder/elbow arthritis | Falls with inability to move shoulder or elbow | New-onset shoulder or elbow pain without trauma |
| Falls with loss of function | Unchanged chronic pain with retained function | Proximal humerus fracture, humeral shaft fracture, distal humerus fracture | Shoulder/elbow arthritis | |
| Any fracture | Hospital discharge without impatient consult | Elbow fracture dislocation, elbow or shoulder dislocation | Chronic shoulder pain with function intact | |
| Any acute changes in function of shoulder or elbow | Hospital consultation, shoulder triaged | Olecranon fracture, clavicle fracture | Self-scheduling without screening | |
| Any neurological issues. Any infection | Chronic cuff disease with unchanged function | New loss of function. Acute-onset neurological complaints. Any infection | Chronic shoulder or elbow dislocations with joint reduced | |
| Hand | Laceration with tendon, nerve injury | Healed lacerations with no tendon, nerve injury. Chronic and resolved infections | Acute laceration with tendon, nerve injury within 2 wk | Lacerations over 2 wk. Chronic infection, chronic osteomyelitis |
| Acute infection | Tendonitis hand, wrist, elbow, trigger finger, DeQuervain's, epicondylitis (tennis/golfer's elbow) | Acute infection | Tendonitis hand, wrist, elbow, trigger finger, DeQuervain's, epicondylitis (tennis/golfer's elbow) | |
| Acute fractures hand, wrist, elbow requiring surgical treatment | Nerve compression syndromes carpal tunnel, cubital tunnel, etc | Acute fractures requiring surgical management | Nerve compression syndromes carpal tunnel, cubital tunnel, etc | |
| Acute injury hand, wrist, elbow within 2 wk | Chronic fracture over 6 wk. Injury hand, wrist, elbow over 2 wk | Acute high-energy hand, wrist, elbow pain without prior evaluation | Nonoperative fractures and fractures over 2 wk. Injury hand, wrist, elbow pain over 2 wk | |
GCT, giant cell tumor.
FIGURE 1Treatment algorithm for elective cases currently in use by some centers. Piedmont Healthcare System, Georgia.
Search Terms Used in PubMed for Each Section
| Delayed treatment of injured nerves | Delayed nerve surgery, delayed vs immediate nerve repair, nerve surgery, prognostic factors affecting nerve recovery, outcomes of peripheral nerve surgery, functional outcomes nerve, timing of nerve repair, late reconstruction nerve, immediate reconstruction nerve, acute reconstruction nerve, poor functional recovery nerve, peripheral nerve regeneration, mechanism of nerve injury, mechanism of nerve regeneration, mechanism of nerve recovery |
| Sensory vs motor nerves | Sensory nerve repair, motor nerve repair, sensory nerve prognostic factors, motor nerve prognostic factors, sensory nerve outcomes, motor nerve outcomes, mixed nerve outcomes, sensory vs motor nerve repair, sensory vs motor nerve outcomes, timing sensory nerves, timing motor nerves, timing mixed nerves, delay sensory nerve repair, delay motor nerve repair, delay mixed nerve repair, delay vs immediate sensory nerve, delay vs immediate motor nerve, delay vs immediate mixed nerve, repair techniques sensory nerve, repair techniques motor nerve, repair techniques mixed nerve |
| Digital nerves | Digital nerve repair, digital nerve prognostic factors, digital nerve outcomes, digital nerve sensory outcomes, digital nerve motor outcomes, timing digital nerves, delay digital nerve repair, immediate digital nerve repair, delay vs immediate digital nerve, repair techniques digital nerve |
| Compartment syndrome | Compartment syndrome peripheral nerve, compartment syndrome nerve changes, compartment syndrome neuropathy, compartment syndrome timing nerve, compartment syndrome timing, compartment syndrome delay, compartment syndrome delayed vs immediate, compartment syndrome irreversible nerve changes, compartment syndrome ischemia, compartment syndrome pediatric, compartment syndrome adult, compartment syndrome pressure |
| Acute nerve compression/dysfunction | Acute compressive neuropathy, acute ulnar nerve compression, acute median nerve compression, acute carpal tunnel, acute cubital tunnel, posttraumatic compressive neuropathy, pressure acute nerve compression, timing acute nerve compression, timing acute nerve decompression, timing traumatic nerve compression, normal healthy carpal tunnel pressure, normal healthy cubital tunnel pressure, acute nerve compression changes, acute nerve compression irreversible nerve changes, acute nerve compression timing, acute nerve release timing, acute carpal tunnel release timing, acute cubital tunnel release timing, acute vs delayed traumatic decompression, acute vs delayed traumatic compressive neuropathy, compressive neuropathy cyst, compressive neuropathy ischemia, posttraumatic neuropathy, postsurgical neuropathy, surgery neuropraxia, timing posttraumatic neuropathy, timing postsurgical neuropathy, timing surgery neuropraxia |
| Chronic nerve compression | Compressive neuropathy, carpal tunnel syndrome, cubital tunnel syndrome, radial tunnel syndrome, ulnar nerve compression, median nerve compression, Guyon's canal decompression, timing acute nerve compression, timing nerve decompression, timing carpal tunnel release, timing cubital tunnel, timing ulnar nerve transposition, delayed nerve decompression, delayed carpal tunnel release, delayed cubital tunnel, delayed ulnar nerve transposition, prolonged nerve compression, prognostic factors carpal tunnel, prognostic factors cubital tunnel, prognostic factors nerve decompression, prognostic factors median nerve decompression, prognostic factors ulnar nerve decompression, time changes peripheral neuropathy, irreversible changes compressive neuropathy, revision* nerve decompression, revision carpal tunnel, revision cubital tunnel, revision radial tunnel, timing revision nerve decompression, timing revision carpal tunnel, timing revision cubital tunnel, timing revision radial tunnel, prognostic factors revision nerve decompression, prognostic factors revision carpal tunnel, prognostic factors revision cubital tunnel |
| Blunt trauma and gunshot wounds | Blunt trauma peripheral nerve, blunt trauma nerve changes, blunt trauma neuropathy, blunt trauma timing nerve, blunt trauma timing, blunt trauma delay, blunt trauma delayed vs immediate, blunt trauma irreversible nerve changes, gunshot wound peripheral nerve, gunshot wound nerve changes, gunshot wound neuropathy, gunshot wound timing nerve, gunshot wound timing, gunshot wound delay, gunshot wound delayed vs immediate, gunshot wound irreversible nerve changes, gunshot wound delayed exploration, gunshot wound immediate exploration, gunshot wound treatment, penetrating wound delay, penetrating wound immediate, penetrating wound exploration, penetrating wound timing |
*All terms including “revision” were also searched using “recurrent” and “recalcitrant.”
FIGURE 2Peripheral nerve injury cascade of events leading to the unidirectional regeneration from proximal to distal stump. ATF2, activating transcription factor 2; ATF3, activating transcription factor 3; ERK, extracellular signal-regulated kinase; CaMKII, Ca2+/calmodulin-dependent protein kinase II; CNTF, ciliary neurotrophic factor; Fra-2, transcription factor; IL-6, interleukin 6; Islet-1, transcription factor; JNK, c-Jun N-terminal kinase; JunD, transcription factor; LIF, leukemia inhibitory factor; NCAM, neural cell adhesion molecule; NfKB, nuclear factor κB; NRG1, neuregulin 1; p-ERK1/2, phosphorylated extracellular signal-regulated kinase; P311, 8-kDa protein with several PEST-like motifs found in neurons and muscle; SC, Scwhann cell; Sox11, transcription factor; STAT3, signal transducer and activator of transcription 3.
Classifications of Nerve Injuries
| Degree of Nerve Injury | Definition of Nerve Injury | Prognosis | Tinel Sign | Surgical Intervention |
|---|---|---|---|---|
| First (neurapraxia) | Segmental demyelination | Favorable | None | None, distal decompression |
| Second (axonotmesis) | Discontinuity of axon and myelin; | Favorable | Present, progressive | None, distal decompression, supercharge procedure |
| Third | Discontinuity of axon, myelin and endoneurium; perineurium and epineurium intact | Favorable | Present, progressive | None, distal decompression, supercharge procedure |
| Fourth | Only the epineurium remains intact | Unfavorable | Present; no progression | Nerve repair, graft, transfer |
| Fifth (neurotmesis) | Complete nerve transection | Unfavorable | Present; no progression | Nerve repair, graft, transfer |
| Sixth | Mixed injury pattern | Variable | Variable | All options may be appropriate |
Table adapted from Moore et al.[5]
FIGURE 3Effect of Schwann cell insufficiency on distal nerve segments after prolonged discontinuity.
Comparison of Patient-Reported Outcomes in Untreated Peripheral Nerve Injuries (Novak et al[27]) Versus Those Having Undergone Operative Intervention
| SF-36 Scores | Physical Function | Role Limit to Physical Health | Role Limit to Emotional Problems | Energy/Fatigue | Emotional Well-Being | Social Function |
|---|---|---|---|---|---|---|
|
| ||||||
| Mean ± SD | 60.0 ± 23.0 | 23.0 ± 33.0 | 45.0 ± 43.0 | 49.0 ± 24.0 | 58.0 ± 23.0 | 57.0 ± 30.0 |
Outcomes of Sensory-Only Peripheral Nerve Repairs
| Predictor | Group | Satisfactory (Good-Excellent) |
|---|---|---|
| Age | ≤16 y | 100% (7/7) |
| 16–25 y | 75.0% (24/32) | |
| 26–40 y | 88.5% (23/26) | |
| >40 y | 75.0% (18/24 | |
| Total (n) | n = 89 | |
| Univariate odds ratio | 0.98 (0.95–1.02), | |
| Sex | Male | 67.4% (29/43) |
| Female | 95.5% (21/22) | |
| Total (n) | n = 65 | |
| Univariate odds ratio (95% CI): female vs male | 10.14 (1.24–83.18), | |
| Nerve | Digital | 80.7% (71/88) |
| Total (n) | n = 88 | |
| Graft length | No graft | 100% (2/2) |
| ≤30 mm | 76.2% (45/54) | |
| 30–50 mm | 33.3% (2/6) | |
| >50 mm | 33.3% (1/3) | |
| Total (n) | n = 65 | |
| Univariate odds ratio (95% CI), | 0.49 (0.30–0.80), | |
| Delay | No delay (<24 h) | 78.6% (33/42) |
| 1–30 d | 75.0% (3/4) | |
| 1–3 mo | 100% (5/5) | |
| 3–6 mo | 84.6% (1/13) | |
| 6–12 mo | 75.0% (3/4) | |
| >12 mo | 100% (2/2) | |
| Total (n) | n = 70 | |
| Univariate odds ratio | 1.04 (0.88–1.23), |
Table adapted from He et al.[32]
Sensory and Range of Motion Recovery Scoring Scales
| Mackinnon-Dellon Scale (modified from British Medical Research Council Score of Sensory Recovery) | S0 (failure): absence of sensibility in the autonomous area of the nerve | |
| S0 (none): no recovery of sensibility in the autonomous zone of the nerve | ||
| S1 (poor): recovery of deep cutaneous pain and tactile sensibility | ||
| S1+ (poor): recovery of superficial pain sensibility | ||
| S2 (poor): recovery of some degree of superficial cutaneous pain and tactile sensibility | ||
| S2+ (poor): as in s2, but with overresponse | ||
| S3 (poor): return of pain and tactile sensibility with disappearance of over response, s2PD >15 mm, m2PD >7 mm | ||
| S3+ (good): return of sensibility as in s3 with some recovery of 2-point discrimination: s2PD, 7–15 mm; m2PD, 4–7 mm | ||
| S4 (excellent): complete recovery: s2PD, 2–6 mm; m2PD, 2–3 mm | ||
| ASSH classification of total active motion (TAM) recovery | Excellent | TAM equal to normal side |
| Good | TAM >75% of normal side | |
| Fair | TAM >50% of normal side | |
| Poor | TAM <50% of normal side | |
Outcomes of Mixed Motor Peripheral Nerve Repairs
| Predictor | Group | Satisfactory (Good-Excellent) | Satisfactory (Good-Excellent) |
|---|---|---|---|
| Age | ≤16 y | 60.9% (56/92) | 66.7% (54/81) |
| 16–25 y | 64.7% (44/68) | 63.6% (35/55) | |
| 26–40 y | 57.8% (38/66) | 60.4% (32/53) | |
| >40 y | 40.9% (18/44) | 47.6% (20/42) | |
| Total (n) | n = 270 | n = 231 | |
| Univariate odds ratio | 0.98 (0.96–0.99), | 0.97 (0.96–0.99), | |
| Sex | Male | 51.0% (77/151) | 55.8% (72/129) |
| Female | 61.4% (35/57) | 73.5% (36/49) | |
| Total (n) | n = 208 | n = 178 | |
| Univariate odds ratio (95% CI), female vs male | 1.53 (0.82–2.85), | 2.19 (1.06–4.52), | |
| Nerve | Ulnar | 52.7% (79/150) | 47.5% (56/118) |
| Median | 57.3% (43/75) | 75.0% (39/52) | |
| Radial | 75.6% (34/45) | 75.4% (46/61) | |
| Total (n) | n = 270 | n = 231 | |
| Univariate | Univariate odds ratio (95% CI), median vs radial | 0.44 (0.19–0.99), | 0.98 (0.42–2.30), |
| Univariate odds ratio (95% CI), | 0.36 (0.17–0.76), | 0.30 (0.15–0.59), | |
| Graft length | No graft | 59.4% (63/106) | 73.8% (59/80) |
| ≤30 mm | 53.8% (14/26) | 48.0% (12/25) | |
| 30–50 mm | 39.3% (11/28) | 28.9% (11/38) | |
| >50 mm | 18.2% (4/22) | 64.9% (37/57) | |
| Total (n) | n = 182 | n = 200 | |
| Univariate odds ratio (95% CI), graft used vs none | 0.48 (0.28–0.82), | 0.40 (0.22–0.73), | |
| Univariate odds ratio (95% CI), gap/cm | 0.91 (0.83–0.99), | 0.93 (0.84–1.03), | |
| Delay | No delay (<24 h) | 10/11 (90.9%) | 6/7 (85.7%) |
| 1–30 d | 21/36 (58.3%) | 56/70 (80.0%) | |
| 1–3 mo | 22/30 (73.3%) | 23/32 (71.9%) | |
| 3–6 mo | 17/39 (43.6%) | 18/34 (52.9%) | |
| 6–12 mo | 11/24 (45.8%) | 5/21 (23.8%) | |
| >12 mo | 25/52 (48.1%) | 10/39 (25.6%) | |
| Total (n) | n = 192 | n = 203 | |
| Odds ratio | 1.00 (0.99–1.01), | 0.93 (0.90–0.97), |
Table adapted from He et al.[32]
Outcomes of Digital Nerve Repair With Varying Delay Times
| Author(s) | Mean Time to Repair in Days | Primary Repair | Nerve Graft | Synthetic Conduit | Vein | Muscle/Muscle-in-Vein | s2PD Mean, mm | m2PD Mean, mm | SWMT Mean |
|---|---|---|---|---|---|---|---|---|---|
| McFarlane and Mayer[ | 170.8 | 13 | 14.9 | ||||||
| Hirasawa et al[ | 186.1 | 10 | 4 | 7.9 | 4.7 | 5.7 | |||
| Sullivan[ | 41.02 | 42 | 11 | 5.6 | |||||
| Walton et al[ | 61 | 115 | 4.5 | 4.02 | |||||
| Rose et al[ | 256.2 | 8.3 | 5.8 | ||||||
| Pereira et al[ | 42.7 | 24 | 12 | 9.4 | |||||
| Tang et al[ | 16 | 3.2 | |||||||
| Segalman et al[ | 19 | 5.5 | 5.0 | 3.74 | |||||
| Battiston et al[ | 112.85 | 18 | 13 | 9.1 | |||||
| Vipond et al[ | 1 | 3 | |||||||
| Lohmeyer et al[ | 115.9 | 12 | 9.6 | ||||||
| Marcoccio and Vigasio[ | 18 | 10.7 | 9.2 | ||||||
| Taras et al[ | 6 | 22 | 5.2 | 5 | |||||
| Rinker and Laiu[ | 3 | 36 | 32 | 8.4 | 6.8 | ||||
| Laveaux et al[ | 1 | 11 | 11 | ||||||
| Chen et al[ | 24 | 26 | 6.7 | 3.62 | |||||
| Taras et al[ | 29 | 18 | 7.1 | 5.4 | |||||
| Stang et al[ | 28 | 9 | |||||||
| Pilanci et al[ | 55.8 | 12 | 7.4 | 3.1 | |||||
| He et al[ | 23.7 | 100 | 12.81 | 3.57 | |||||
| Kim et al[ | 5.9 | 5.1 | 3.81 | ||||||
| Rinker et al[ | 13 | 37 | 7.1 | 6.7 | |||||
| Wong et al[ | 14.7 | 5.09 | |||||||
| Fakin et al[ | 93 | 10.6 | 2.7 | ||||||
| Klein et al[ | 5 | 81 | 4 |
Table adapted from Kim et al.[97]
Carpal Tunnel Surgery: Outcomes Predictors Based on SSS and FSS
| Variables Predicting Change in SSS | |||||
|---|---|---|---|---|---|
| Predictors |
| SE |
| Standard Coefficient β | 95% CI |
| Age | 0.002 | 0.001 | 0.134 | 0.077 | −0.001 to 0.004 |
| Duration of symptoms | 0.056 | 0. 20 | 0.007 | 0.137 | 0.015–0.096 |
| Electrophysiological severity | 0.231 | 0.016 | <0.001 | 0.767 | 0.199 to 0.263 |
| Thenar muscle atrophy | −0.003 | 0.028 | 0.908 | −0.006 | −0.58 to 0.052 |
BMI, body mass index; FSS, Functional Status Scale; SSS, Symptom Severity Scale.
Table adapted from Alimohammadi et al.[159]
Risk Factors for Postoperative Infection Following Open Cubital Tunnel Release
| Variable | Odds Ratio | 95% CI |
|
|---|---|---|---|
| Significant risk factors for infection after open cubital tunnel release | |||
| Demographics | |||
| Age <65 y | 2.08 | 1.52–2.85 | <0.001 |
| Tobacco use | 1.65 | 1.31–2.07 | <0.001 |
| Body mass index, kg/m2 | |||
| 30–40 (obesity) | 1.52 | 1.18–1.94 | <0.001 |
| ≥40 (morbid obesity) | 1.53 | 1.16–2.01 | 0.002 |
| Male sex | 1.32 | 1.07–1.63 | 0.008 |
| Comorbidity | |||
| Hemodialysis use | 2.47 | 1.19–5.16 | 0.016 |
| Chronic anemia | 2.24 | 1.72–2.90 | <0.001 |
| Inflammatory arthritis | 1.43 | 1.08–1.88 | 0.012 |
| Depression | 1.36 | 1.09–1.70 | 0.007 |
| Hyperlipidemia | 1.33 | 1.00–1.76 | 0.049 |
| Chronic lung disease | 1.29 | 1.04–1.60 | 0.022 |
| Factors not increasing the risk for infection after open cubital tunnel release | |||
| Demographics | |||
| Low body mass index (<19 kg/m2) | 0.97 | 0.31–3.07 | 0.962 |
| Comorbidity | |||
| Hypercoagulable state | 1.16 | 0.78–1.72 | 0.459 |
| Alcohol abuse | 1.12 | 0.83–1.50 | 0.468 |
| Diabetes mellitus | 1.08 | 0.87–1.34 | 0.507 |
| Chronic kidney disease | 1.06 | 0.81–1.40 | 0.675 |
| Peripheral vascular disease | 1.06 | 0.82–1.39 | 0.648 |
| Hypothyroidism | 1.05 | 0.84–1.31 | 0.668 |
| Hypertension | 1.03 | 0.75–1.41 | 0.852 |
| Chronic liver disease | 1.01 | 0.75–1.36 | 0.942 |
| Congestive heart failure | 0.82 | 0.63–1.08 | 0.159 |
| Coronary artery disease | 0.77 | 0.61–0.97 | 0.011 |
Table adapted from Camp et al.[161]
Primary Versus Revision Cubital Tunnel Syndrome
| Primary | Revisions |
| |
|---|---|---|---|
| Final subjective symptoms according to patient group | |||
| Relief after primary surgery | 27 (96%) | 14 (50%) | <0.001 |
| Relief after revision surgery | — | 22 (79%) | |
| Symptoms currently | 22 (79%) | 24 (85%) | 0.48 |
| • Paresthesias | 17 (61%) | 20 (71%) | 0.39 |
| Symptoms constant, intermittent, or absent | 0.03 | ||
| • Constant | 5 (18%) | 15 (53%) | |
| • Intermittent | 17 (61%) | 9 (32%) | |
| • Absent | 6 (21%) | 4 (15%) | |
| Physical examination findings according to patient group | |||
| Elbow extension, ° | 2 (0–20) | 12 (0–35) | <0.001 |
| Elbow flexion, ° | 142 (120–145) | 137 (125–150) | 0.09 |
| Positive Tinel sign | 15 (54%) | 14 (50%) | 0.79 |
| Nerve tender at elbow | 4 (14%) | 12 (43%) | 0.02 |
| 1st DI strength (out of 5) | 4.5 (2–5) | 4.4 (3–5) | 0.87 |
| Grip strength, kg | 33 (11–54) | 28 (8–63) | 0.13 |
| Key pinch strength, kg | 8 (4–15) | 5 (3–16) | 0.03 |
| Ring/little finger 2-point discrimination, mm | 6 (5–15) | 7 (6–15) | 0.02 |
| Wartenberg sign | 2 (7%) | 9 (32%) | 0.02 |
| Froment sign | 4 (14%) | 7 (25%) | 0.31 |
| McGowan grading according to patient group | |||
| Final McGowan grade | 0.01 | ||
| 0 | 10 (36%) | 6 (21%) | |
| I | 12 (43%) | 5 (18%) | |
| IIA | 2 (7%) | 12 (43%) | |
| IIB | 3 (11%) | 3 (11%) | |
| III | 1 (3%) | 2 (7%) | |
| Change in McGowan grade after surgery | 0.003 | ||
| Improved | 18 (64%) | 7 (25%) | |
| No change | 8 (29%) | 15 (54%) | |
| Worse | 2 (7%) | 6 (21%) | |
Table adapted from Aleem et al.[164]
Outcomes After Revision Carpal Tunnel Surgery
| Study | Level of Evidence | No. of Hands | Method/Follow-Up | Resolved or Improved, n (%) | Complications and Patient-Reported Outcomes | ||
|---|---|---|---|---|---|---|---|
| Recurrent or persistent CTS | Endoscopic revision CTR | Teoh and Tan[ | IV | 9 | Endoscopic revision | 9 (100) | 0 complications |
| Luria et al[ | IV | 41 | Endoscopic revision | 37 (90) | 0 complications | ||
| Total | 50 | 46 (92) | 0 (0%) complications | ||||
| Open revision CTR and neurolysis | Langloh and Linscheid[ | IV | 33 | External neurolysis | 28 (85) | Complications: NR | |
| Wadstroem and Nigst[ | IV | 27 | External and internal neurolysis | 22 (81) | NA | ||
| O'Malley et al[ | IV | 20 | External neurolysis | 12 (60) | 1 superficial wound infection | ||
| Chang and Dellon[ | IV | 35 | External and internal neurolysis | 29 (83) | Complications: NR | ||
| Cobb et al[ | IV | 131 | External and internal neurolysis | 87 (66) | 9 delayed wound healing | ||
| Duclos and Sokolow[ | IV | 13 | External neurolysis | 12 (92) | NA | ||
| Hulsizer et al[ | IV | 30 | External neurolysis | 18 (60) | Complications: NR | ||
| Forman et al[ | IV | 22 | External neurolysis | 21 (95) | 2 scar tenderness and stiffness | ||
| Beck et al[ | III | 28 | External neurolysis | 23 (82) | Complications: NR | ||
| Total | 339 | 252 (74) | 20 (6%) complications | ||||
| Vein wrap | Sotereanos et al.[ | IV | 6 | Saphenous vein wrap | 6 (100) | 1 transient venous insufficiency | |
| Varitimidis et al[ | IV | 15 | Saphenous vein wrap | 15 (100) | 1 transient local swelling at leg | ||
| Total | 21 | 21 (100) | 2 (10%) complications, transient | ||||
| Synthetic wrap | Soltani et al.[ | IV | 9 | Collagen synthetic wrap | 8 (89) | Complications: NR | |
| Kokkalis et al.[ | IV | 2 | Collagen synthetic wrap | 2 (100) | 0 complications | ||
| Kokkalis et al[ | IV | 10 | Collagen synthetic wrap | 10 (100) | 0 complications | ||
| Total | 21 | 21 (95) | 0 (0%) complications | ||||
| Recurrent or persistent CTS | Hypothenar fat flap | Strickland et al[ | IV | 62 | Hypothenar fat flap (62) + internal neurolysis (7) | 55 (89) | 1 ulnar digital nerve paresthesias |
| Giunta et al[ | IV | 9 | Hypothenar fat flap | 8 (89) | NA | ||
| Mathoulin et al[ | IV | 45 | Hypothenar fat flap | 43 (96) | 2 scar pain and edema, transient | ||
| Craft et al[ | IV | 28 | Hypothenar fat flap | 26 (93) | Complications: NR | ||
| Stutz et al[ | III | 11 | Hypothenar fat flap | 8 (73) | 2 hypertrophic scar | ||
| Fusetti et al[ | IV | 20 | Hypothenar fat flap | 18 (90) | 16 two-point discrimination resolved to normal | ||
| Karthik et al[ | IV | 27 | Hypothenar fat flap | 24 (89) | Complications: NR | ||
| Wichelhaus et al[ | IV | 18 | Hypothenar fat flap | 16 (89) | 2 hypertrophic scar | ||
| Athlani and Haloua[ | IV | 34 | Hypothenar fat flap | 34 (100) | VAS decreased from 6.4 to 1.4 ( | ||
| Total | 254 | 232 (91) | 9 (4%) complications | ||||
| Synovial flap | Wulle[ | IV | 27 | Synovial flap | 25 (93) | NA | |
| Stutz et al[ | III | 16 | Synovial flap | 9 (56) | 1 delayed wound healing | ||
| Murthy et al[ | IV | 45 | Synovial flap | 43 (96) | 1 scar pain | ||
| Total | 88 | 77 (88) | 2 (2%) complications | ||||
| Multiple surgical methods (outcomes not reported separately) | Strasberg et al[ | IV | 45 | External and internal neurolysis | 24 (53) | Complications: NR | |
| Varitimidis et al[ | IV | 24 | External neurolysis alone (7) | 24 (100) | Complications: NR | ||
| Jones et al[ | IV | 55 | External neurolysis (41) | 45 (82) | Complications: NR | ||
| Recurrent or persistent CTS | Zieske et al[ | III | 97 | External neurolysis (97) | NR | All groups had decreases in VAS pain scores postop | |
| Djerbi et al[ | IV | 38 | Neurolysis (22) | 26 (68) | Complications: NR | ||
| Total | 162 | 119 (73) |
*P < 0.01.
Avg, average; CTR, carpal tunnel release; CTS, carpal tunnel syndrome; CTSFSS, Carpal Tunnel Syndrome Functional Status Score; CTSSS, Carpal Tunnel Syndrome Symptom Severity Score; DASH, Disabilities of the Arm, Shoulder, and Hand Score; NA, not available; NR, not reported; PRO, patient self-reported outcomes, validated outcomes include DASH, PRWE; RSD, reflex sympathetic dystrophy (ie, chronic regional pain syndrome); RTA, return to recreational activities; RTW, return to work; UWSS, University of Washington patient satisfaction score; VAS, visual analog scale.
Table adapted from Lauder et al.[198]
FIGURE 4Management of peripheral nerve transection.
Medically Necessary, Time-Sensitive Procedures
| Procedure Factors | 1 | 2 | 3 | 4 | 5 | Score (1–5) |
|---|---|---|---|---|---|---|
| OR time, min | <30 | 30–60 | 60–120 | 120–180 | ≥180 | |
| Estimated length of stay | Outpatient | 23 h | 24–48 h | ≤3 d | >4 d | |
| Postoperative ICU need, % | Very unlikely | <5 | 5–10 | 10–25 | ≥25 | |
| Anticipated blood loss, cc | <100 | 100–250 | 250–500 | 500–750 | ≥75 | |
| Surgical team size | 1 | 2 | 3 | 4 | >4 | |
| Intubation probability | ≤1% | 1%–5% | 5%–10% | 10%–25% | ≥25% | |
| Surgical site | None of the following | Abdominopelvic MIS surgery | Abdominopelvic open surgery, infraumbilical | Abdominopelvic open surgery, supraumbilical | OHNS/upper GI/thoracic | |
| Disease factors | 1 | 2 | 3 | 4 | 5 | Score (1–5) |
| Nonoperative treatment option effectiveness | None available | Available, <40% as effective as surgery | Available, 40%–60% as effective as surgery | Available, 60%–95% as effective as surgery | Available, equally effective | |
| Nonoperative treatment option resource/exposure risk | Significantly worse/not applicable | Somewhat worse | Equivalent | Somewhat better | Significantly better | |
| Impact of 2-wk delay in disease outcome | Significantly worse | Worse | Moderately worse | Slightly worse | No worse | |
| Impact of 2-wk Delay in surgical difficulty/risk | Significantly worse | Worse | Moderately worse | Slightly worse | No worse | |
| Impact of 6-wk delay in disease outcome | Significantly worse | Worse | Moderately worse | Slightly worse | No worse | |
| Impact of 6-wk delay in surgical difficulty/risk | Significantly worse | Worse | Moderately worse | Slightly worse | No worse | |
| Patient factors | 1 | 2 | 3 | 4 | 5 | Score (1–5) |
| Age, y | <20 | 20–40 | 40–50 | 50–65 | >65 | |
| Lung disease (asthma, COPD, CF1) | None | Minimal (rare inhaler) | >Minimal | |||
| Obstructive sleep apnea | Not present | Mild/Moderate (no CPAP) | On CPAP | |||
| CV disease (HTN, CHF, CAD) | None | Minimal (no meds) | Mild (≤1 med) | Moderate (2 meds) | Severe (≥3 meds) | |
| Diabetes | None | Mild (no meds) | Moderate (PO meds only) | >Moderate (insulin) | ||
| Immunocompromised2 | No | Moderate | Severe | |||
| ILI3 Sx's (fever, cough, sore throat, body aches, diarrhea) | None, asymptomatic | Yes | ||||
| Exposure to known COVID-19–positive person in the past 14 d | No | Probably not | Possibly | Probably | Yes | |
| Total Score: |
Each row is scored, and all scores are added to produce a cumulative score (range, 21–105). A higher total score is associated with poorer perioperative outcomes, increased COVID-19 transmission, and/or increased hospital resource requirements.
CAD, coronary artery disease; CHF, congestive heart failure; CV, cardiovascular; COPD, chronic obstructive pulmonary disease; HTN, hypertension; ICU, intensive care unit.
Table adapted from Prachand et al.[1]
MeNTS Possible Score Ranges for Common Nerve Procedures
| Procedure Factors | Sharp Laceration of Digital Nerve | Ulnar Elbow (MM) | Carpal Tunnel | Neuroma (Palmar Nerve) | |
|---|---|---|---|---|---|
| OR time | 1–2 | 2–3 | 1 | 2 | |
| Estimated length of stay | 1 | 1 | 1 | 1 | |
| Postoperative ICU need | 1 | 1 | 1 | 1 | |
| Anticipated blood loss | 1 | 1 | 1 | 1 | |
| Surgical team size | 4 | 4 | 4 | 4 | |
| Intubation probability | 1 | 1 | 1 | 1 | |
| Surgical site | 1 | 1 | 1 | 1 | |
| Disease factors | |||||
| Nonoperative treatment, pain medication | 2 | 1 | 2 | 2 | |
| Nonoperative treatment, pain medication | 5 | 1 | 5 | 5 | |
| Impact of 2-wk delay | 3 | 3 | 5 | 3 | |
| Impact of 2-wk delay | 2 | 2 | 5 | 5 | |
| Impact of 6-wk delay | 2 | 1 | 4 | 3 | |
| Impact of 6-wk delay | 2 | 2 | 5 | 5 | |
| Score (+ possible scores from factors below) | 27 (+8 → 40) | 22 (+8 → 40) | 36 (+8 → 40) | 34 (+8 → 40) | |
| Patient factors | 1 | 2 | 3 | 4 | 5 |
| Age, y | <20 | 20–40 | 40–50 | 50–65 | >65 |
| Lung disease | None | Minimal | > Minimal | ||
| Obstructive sleep apnea | Not present | Mild/moderate (no CPAP) | On CPAP | ||
| CV disease | None | Minimal | Mild | Moderate | Severe |
| Diabetes | None | Mild | Moderate | >Moderate (insulin) | |
| Immunocompromised2 | No | Moderate | Severe | ||
| ILI3 Sx's (fever, cough, sore throat, body aches, diarrhea) | None, asymptomatic | Yes | |||
| Exposure to known COVID-19–positive person in the past 14 d | No | Probably not | Possibly | Probably | Yes |
A higher total score is associated with poorer perioperative outcomes, increased COVID-19 Transmission, and/or increased hospital resource requirements.
CAD, coronary artery disease; CHF, congestive heart failure; CPAP, continuous positive airway pressure; CV, cardiovascular; COPD, chronic obstructive pulmonary disease; HTN, hypertension; ICU, intensive care unit; MeNTS, Medically Necessary, Time-Sensitive Procedures; PO, per os (oral administration).
Outcomes Predictors for in Situ Ulnar Nerve Decompression
| Variable | Unsatisfactory Group (n = 27) | Satisfactory Group (n = 208) |
|
|---|---|---|---|
| Age (y) | 54.1 ± 11.3 | 53.2 ± 10.6 | 0.681 |
| Sex | 0.83 | ||
| Male | 17 | 137 | |
| Female | 10 | 71 | |
| BMI, kg/m2 | 24.1 ± 3.1 | 23.5 ± 2.7 | 0.287 |
| Tobacco use | 0.649 | ||
| Yes | 6 | 59 | |
| No | 21 | 149 | |
| Alcohol use | 0.614 | ||
| Yes | 4 | 42 | |
| No | 23 | 166 | |
| Hypertension | 0.438 | ||
| Yes | 7 | 39 | |
| No | 20 | 169 | |
| Diabetes mellitus | 0.748 | ||
| Yes | 2 | 23 | |
| No | 25 | 185 | |
| Disease duration, mo | 17.1 ± 6.7 | 13.8 ± 7.4 | 0.029 |
| Preoperative severity | 0.004 | ||
| Severe | 25 | 137 | |
| Not severe | 2 | 71 | |
| MCV, m/s | 28.2 ± 10.5 | 34.1 ± 12.8 | 0.023 |
| SCV, m/s | 23.4 ± 11.7 | 27.6 ± 8.4 | 0.021 |
BMI, body mass index; MCV, motor conduction velocity; SCV sensory conduction velocity.
Table adapted from Kong et al.[160]